Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3904 results about "Fibrosis" patented technology

A condition where there is thickening or scarring of tissues.

Compositions and methods for modulating circulating factors

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.
Owner:FLAGSHIP ENTREPRENEURSHIP & INNOVATION NO 7 CO LTD

Methods of treatment for cystic fibrosis

This disclosure provides methods of treating cystic fibrosis or a CFTR-mediated disease comprising administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. The disclosure also provides pharmaceutical compositions comprising Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, and optionally comprising one or more additional CFTR-modulating agents.
Owner:VERTEX PHARMACEUTICALS INC

Substituted piperidinediones for targeted protein degradation

PCT designated stage expiredWO2025024521A1Organic active ingredientsAntipyreticInterstitial lung diseasePericarditis
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.
Owner:MONTE ROSA THERAPEUTICS AG

Cardiac muscle magnetic resonance image fibrosis classification method based on convolutional neural network

The invention proposes a myocardial magnetic resonance image fibrosis classification method based on a convolutional neural network, and relates to the technical field of image processing, and the method comprises the steps: obtaining an original magnetic resonance image of a to-be-detected target from a magnetic resonance imaging device, and carrying out the preprocessing of the original magnetic resonance image; segmenting the preprocessed magnetic resonance image into a plurality of sub-regions based on the connected features, each sub-region representing an independent connected part in the image; constructing a gray scale measurement function for each sub-region, quantifying the gray scale distribution characteristics of each sub-region, and identifying the sub-region with the minimum gray scale measurement function value as a fibrosis tissue sub-region by comparing the gray scale measurement function values of the sub-regions; features are extracted from the identified fibrosis tissue sub-regions to serve as input of the convolutional neural network model, the fibrosis tissue sub-regions are classified, the fibrosis stages to which the fibrosis tissue sub-regions belong are output, and the accuracy of classification of the fibrosis tissue is improved.
Owner:TIANJIN UNIV OF SCI & TECH +1

Substituted pyrazolo piperidine carboxylic acids

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
Owner:BAYER AG

Antibody binding to il-11, antigen-binding fragment thereof, and uses thereof

PCT designated stage expiredWO2024250838A1AntipyreticAnalgesicsAntigenAutoimmune condition
The present invention relates to the field of biomedicine, and specifically provides an antibody binding to IL-11 or antigen-binding fragment thereof, comprising three heavy-chain complementarity-determining regions respectively represented by HCDR1, HCDR2, and HCDR3, and three light-chain complementarity-determining regions respectively represented by LCDR1, LCDR2, and LCDR3, the antibody or antigen-binding fragment thereof being selected from A-I, A-II, A-III, or A-IV. The provided antibody or antigen-binding fragment thereof has high binding capacity to the IL-11 antigen and can block the IL-11 antigen from binding to receptors thereof, thus effectively inhibiting the pro-fibrotic effect of IL-11 and inhibiting or preventing the generation or proliferation of fibroblasts, and can be effectively used for treating or preventing human fibrotic diseases, inflammation, cancers, or autoimmune diseases.
Owner:BEIJING DONGFANG BIOTECH CO LTD +1

Anti-GAL3 antibodies and uses thereof

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.
Owner:TRUEBINDING INC

Methods for treating or preventing asthma by administering an IL-4R antagonist

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.
Owner:SANOFI BIOTECH SAS +1

Methods of using activin receptor type ii variants

PCT designated stage expiredWO2024238920A1Peptide/protein ingredientsReceptors for cytokines/lymphoines/interferonsActivin Receptors Type IICardiac functioning
The invention features methods for the treatment of a cardiovascular disease using a polypeptide containing an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. The polypeptide may include an extracellular ActRII variant fused to an Fc domain monomer. Treatment of a cardiovascular disease with a polypeptide described herein may reduce fibrosis, reduce inflammation, reduce cardiac remodeling, improve cardiac function, improve ventricular function, or slow or inhibit disease progression, which may reduce or delay the need for coronary revascularization, heart valve repair or replacement, implantation of a cardioverter-defibrillator, cardiac resynchronization therapy, a ventricular assist device, or a heart transplant.
Owner:KEROS THERAPEUTICS INC

Synergistic nano-drug for removing fibrosis and inhibiting pancreatic cancer metastasis and preparation method of nano-drug

The invention belongs to the field of pharmaceutical preparations, and particularly discloses a synergistic nano-drug for understanding fibrosis and inhibiting pancreatic cancer metastasis and a preparation method of the synergistic nano-drug, excipient-related toxicity is avoided through self-assembly of small-molecule prodrugs, the drug loading rate is high, homologous targeting and receptor protein-mediated active targeting on fibrotic adhesion interstitial substances are achieved through coating of a hybrid membrane, and the nano-drug has the advantages of being high in bioavailability, high in bioavailability and the like. Through the response of prodrug molecules to ROS, massive, rapid and traceless drug release in fibrotic adhesion interstitial substances is realized, and the self-limiting characteristic of release of responsive micromolecular drugs is relieved; the released medicines Cap and CA can inhibit fibrosis signals / proteins at the same time and synergistically defibration; along with the proceeding of defibrosis, Cap and CA which are rapidly and seamlessly released in pancreatic cancer cells can simultaneously inhibit a metastasis / invasion signal channel of the pancreatic cancer cells and synergistically inhibit the occurrence of metastasis; the defibration process and the metastasis inhibition process are dynamically coordinated, and a new way is provided for defibration in pancreatic cancer treatment.
Owner:LINGNAN NORMAL UNIV

Methods of treating fibrosis

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.
Owner:ENDEAVOR BIOMEDICINES INC

Methods of improving lung function

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.
Owner:ENDEAVOR BIOMEDICINES INC

Methods of treating fibrosis

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Owner:ENDEAVOR BIOMEDICINES INC

One-step cell membrane bionic lipid nanoparticles as well as preparation method, device and application thereof

The invention discloses a one-step cell membrane bionic lipid nanoparticle as well as a preparation method, a device and application thereof, and belongs to the field of microfluidics preparation and bionic preparation. The one-step preparation chip is constructed by combining microfluidic and alternating current stimulation technologies, the preparation method is simple and convenient, and conditions are controllable. The fusion efficiency on cell membranes and lipid nanoparticles is better, the protection capability on protein components is better, and the clinical transformation possibility is good. The cell membrane bionic lipid nanoparticles can effectively carry various drugs, achieve accurate targeting of the recognition ability of pulmonary alveolar damaged pulmonary epithelial cells, achieve more efficient drug delivery ability, can achieve effective intervention in the early stage of pulmonary fibrosis, and have broad application prospects.
Owner:JINHUA INSTITUTE OF ZHEJIANG UNIVERSITY

Methods of treatment for cystic fibrosis

This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof.The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
Owner:VERTEX PHARMACEUTICALS INC

Compositions and methods for modulating cytokines

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immunological disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.
Owner:FLAGSHIP ENTREPRENEURSHIP & INNOVATION NO 7 CO LTD

Antibody binding to IL-11, antigen binding fragment and application thereof

The present invention relates to the field of biological medicine, and particularly provides an IL-11 binding antibody or an antigen binding fragment thereof, the antibody comprises three heavy chain complementarity determining regions represented by HCDR1, HCDR2 and HCDR3 respectively and three light chain complementarity determining regions represented by LCDR1, LCDR2 and LCDR3 respectively, and the antibody or the antigen binding fragment thereof is selected from A-I, A-II, A-III or A-IV. The antibody or the antigen binding fragment thereof provided by the invention has relatively high binding capacity with the IL-11 antigen, and can block the binding of the IL-11 antigen and a receptor thereof, so that the fibrosis promoting effect of the IL-11 is effectively inhibited, the generation or proliferation of fibrocytes is inhibited or prevented, and the anti-fibrosis effect of the IL-11 is improved. The compound can be effectively used for treating or preventing human fibrosis diseases, inflammations, cancers or autoimmune diseases.
Owner:BEIJING DONGFANG BIOTECH CO LTD +1

Activin receptor type IIA variants and methods of use thereof

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.
Owner:KEROS THERAPEUTICS INC

Preparation method and application of lactic acid bacteria metagen

The invention belongs to the technical field of microorganisms, and particularly relates to probiotic characteristics of lactic acid bacteria and a relieving effect of a metagen of the lactic acid bacteria on pulmonary fibrosis. The invention discloses pediococcus pentosaceus ZFML001, and the preservation number of the pediococcus pentosaceus ZFML001 is CCTCC (China Center for Type Culture Collection) NO: M 2024601. The invention also provides a metagen prepared from the pediococcus pentosaceus ZFML001 at the same time, and provides an application of the metagen in preparation of a medicine for relieving or assisting in treatment of pulmonary fibrosis. The invention further provides the application of the metagen in preparation of a medicine for relieving or assisting in treatment of pulmonary fibrosis.
Owner:ZHEJIANG GONGSHANG UNIVERSITY

Combination therapy

Provided herein is a method for the treatment or prevention of a disease or disorder, the method comprising administering a PDE4 inhibitor and a GLP1 receptor agonist to a subject, wherein the disease or disorder is selected from: an inflammatory disease, an autoimmune disease, fibrosis, a neurodegenerative disease, a musculoskeletal disorder, a metabolic disease or disorder, alcoholic liver disease (ALD), cardiovascular disease and a gastrointestinal disorder.
Owner:UNION THERAPEUTICS AS

Diabetes kidney lesion risk detection method and system based on ultrasound

The invention discloses an ultrasound-based diabetic renal lesion risk detection method and system, and relates to the technical field of ultrasonic detection.According to the system, through continuous scanning of a two-dimensional ultrasonic probe, an elastic imaging probe and a Doppler probe, the shape, structure, blood flow characteristics and cortex images of the kidney are obtained; an image processing technology is adopted for preprocessing, space registration and fusion, and a kidney area is automatically segmented; according to the extracted kidney tissue characteristics, calculating an atrophy risk coefficient and a fibrosis risk coefficient, and comparing with a standard threshold value to evaluate the kidney lesion risk; calculating a comprehensive risk coefficient in combination with blood glucose, urine protein and diet data, and evaluating diet influence risks; a renal lesion risk assessment model is constructed by using a convolutional neural network and a machine learning algorithm, a renal lesion prediction function is generated, and the system can accurately assess the renal lesion risk of a diabetic patient and provide early diagnosis and personalized treatment suggestions.
Owner:晋江市医院(上海市第六人民医院福建医院)

Devices and methods for ablation of the skin

Disclosed herein are apparatuses, systems, kits, and methods for treating skin, such as skin tightening or for treating diseases, disorders, and conditions that would benefit from tissue area or volume reduction, skin restoration, skin tightening, skin lifting, and / or skin repositioning and / or for generally improving skin function or appearance (e.g., the removal of unwanted skin features or irregularities such as sebaceous glands, sweat glands, hair follicles, necrosis, and fibrosis). Such apparatuses, systems, kits, and methods comprise an apparatus having a handheld main body and a detachably attachable tip comprising one or more needles.
Owner:CYTRELLIS BIOSYST

Methods, apparatuses, and systems for the treatment of pulmonary disorders

ActiveUS20250064510A1ElectrotherapySurgical instruments for heatingDiseaseAcute bronchitis
Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.
Owner:GALVANIZE THERAPEUTICS INC